• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Janssen’s Spravato esketamine nasal spray gets positive opinion from CHMP

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Janssen’s Spravato esketamine nasal spray for use with either a selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI) for the treatment of treatment-resistant major depressive disorder, the company said. A final decision by the EC is expected by the end of 2019. Spravato has been approved in the US for the treatment of treatment-resistant depression since March 2019.

Janssen-Cilag European Therapeutic Area Lead for Mood Disorders Allitia DiBernardo said, “MDD affects approximately 40 million people across Europe and is the leading cause of disability worldwide. Of these people, about one third do not respond to currently available treatments. Janssen is committed to improving outcomes for patients with treatment-resistant major depressive disorder, and we look forward to bringing a new treatment option to people who need it most.”

Janssen Research & Development Global Head, Neuroscience Therapeutic Area, Husseini K. Manji said, “We are pleased with CHMP’s opinion and their recommendation to approve esketamine nasal spray as a potential therapy for adults living with treatment-resistant major depressive disorder. For decades there have been no new treatment options for these patients. Esketamine nasal spray represents a new way to manage TRD with a unique and novel mode of administration.”

Read the Janssen press release.

Share

published on October 18, 2019

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Catalent banner
    © 2025 OINDPnews